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1. INTRODUCTION {#jdb12963-sec-0006}
===============

A worldwide diabetes epidemic continues to unfold; according to the International Diabetes Federation, in 2017 there were 425 million people affected by diabetes worldwide, with most having type 2 diabetes (T2D).[1](#jdb12963-bib-0001){ref-type="ref"} Due to the progressive nature of T2D, most patients will eventually require insulin therapy.[2](#jdb12963-bib-0002){ref-type="ref"}, [3](#jdb12963-bib-0003){ref-type="ref"} Both international and Chinese treatment guidelines recommend the initiation of basal insulin (BI) for patients unable to achieve glycemic targets with one to two oral antidiabetic drugs (OADs).[4](#jdb12963-bib-0004){ref-type="ref"}, [5](#jdb12963-bib-0005){ref-type="ref"}, [6](#jdb12963-bib-0006){ref-type="ref"}

Despite the recommendations of evidence‐based guidelines, large gaps exist globally in the achievement of glycemic control for patients with T2D receiving BI in clinical practice.[7](#jdb12963-bib-0007){ref-type="ref"}, [8](#jdb12963-bib-0008){ref-type="ref"}, [9](#jdb12963-bib-0009){ref-type="ref"} For example, a retrospective analysis using data from a US claims database indicated that the proportion of patients achieving HbA1c \<7.0% (53 mmol/mol) was similar for BI users at baseline (26%) and at 3 months follow‐up (27%).[10](#jdb12963-bib-0010){ref-type="ref"} Furthermore, the large Observational Registry of Basal Insulin Treatment (ORBIT) study found that BI was initiated relatively late with mean HbA1c of 9.6% (81 mmol/mol).[11](#jdb12963-bib-0011){ref-type="ref"} Another multicenter cross‐sectional survey conducted in China revealed that of 80 973 patients treated by BI plus OAD(s), only 26.21% achieved HbA1c \<7% (53 mmol/mol).[12](#jdb12963-bib-0012){ref-type="ref"} Thus, achieving and maintaining glycemic control in patients receiving BI therapy is a global challenge.

In China, the China Guideline for Type 2 Diabetes is enforced by the Chinese Diabetes Society (CDS) by creating awareness and knowledge exchange.[6](#jdb12963-bib-0006){ref-type="ref"} However, the awareness and implementation of evidence‐based T2D treatment guidelines varies across different geographical regions of China, hospital grades, professional status, and specialities. Reportedly, less than 30% of physicians completely understand the guidelines and apply them in practice.[13](#jdb12963-bib-0013){ref-type="ref"} For several decades, quality improvement interventions directed at patients, doctors, and health systems have aimed to address gaps in the management of T2D not fully addressed through new therapeutics or devices.[14](#jdb12963-bib-0014){ref-type="ref"}, [15](#jdb12963-bib-0015){ref-type="ref"} Results from a large meta‐analysis showed that predefined quality improvement strategies led to improvements in glycemic control.[14](#jdb12963-bib-0014){ref-type="ref"}

However, to the best of the authors\' knowledge, there have been no previous quality improvement initiatives that focused on patients already receiving BI therapy,[16](#jdb12963-bib-0016){ref-type="ref"}, [17](#jdb12963-bib-0017){ref-type="ref"}, [18](#jdb12963-bib-0018){ref-type="ref"} whose glycemic control is typically relatively poor.[10](#jdb12963-bib-0010){ref-type="ref"}, [11](#jdb12963-bib-0011){ref-type="ref"}, [12](#jdb12963-bib-0012){ref-type="ref"} Furthermore, although both nurses and patients play an important role in quality improvement initiatives, physicians are particularly key in adopting guidelines and improving glycemic control for patients receiving insulin.[19](#jdb12963-bib-0019){ref-type="ref"}, [20](#jdb12963-bib-0020){ref-type="ref"}, [21](#jdb12963-bib-0021){ref-type="ref"} The aim of the BEYOND II study was to evaluate the effectiveness of physician‐targeted education for improving management in T2D patients receiving BI therapy.

2. METHODS {#jdb12963-sec-0007}
==========

2.1. Study design {#jdb12963-sec-0008}
-----------------

The BEYOND II study was a multicenter open‐label observational study conducted at centers across China from October 2015 to March 2017 (Table [S1](#jdb12963-supitem-0001){ref-type="supplementary-material"}). The study consisted of a baseline sample survey to evaluate glucose control in the hospital before education, followed by a 6‐month physician‐targeted education program, and ending with a post‐education sample survey to evaluate glucose control in the hospital after education (Figure [S1](#jdb12963-supitem-0001){ref-type="supplementary-material"}). During both survey periods, physicians at each study site were mandated to consecutively enroll 100 individuals (200 in total) with T2D receiving BI and collect laboratory test results from routine practice. Patients enrolled at the time of the post‐educational survey could be different to those enrolled at the time of the baseline survey. To reduce selection bias, all data were collected within 2 months of recruitment of the first patient at each center and recorded in an electronic case report form (e‐CRF). Participating physicians\' confidence and daily practice in BI treatment were also assessed at baseline and after the education intervention using questionnaires.

The study protocol was approved by the Clinical Trial Ethics Committee of the Third Affiliated Hospital, Sun Yat‐sen University (Reference no. \[2015\] 2‐152 on July 21, 2015). The study was conducted in accordance with the Declaration of Helsinki and in‐line with The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use guidelines for Good Clinical Practice (GCP) and Chinese GCP. Written informed consent was obtained from each study participant. This study is registered in the Chinese Clinical Trials registry (ID: ChiCTR‐OOC‐15006935).

2.2. Study center and physician selection criteria {#jdb12963-sec-0009}
--------------------------------------------------

Endocrinology departments at Tier 3 or Tier 2 hospitals across China with a head of department willing to support the implementation of the education and adopt a standard T2D treatment pathway were eligible for inclusion in this study. Most T2D patients in China are treated at Tier 2 and 3 hospitals; therefore, eligible study centers represented the standard of care in China.

Heads of enrolled endocrinology departments conferred with departmental physicians and nominated participants. An inclusion target of ≥60% of outpatient endocrinologists at each study center was set to provide a representative sample of the overall treatment quality. Participating physicians were required to complete the whole study process, and replacement of physicians during the study was not allowed.

2.3. Patient inclusion criteria {#jdb12963-sec-0010}
-------------------------------

Adults (age ≥ 18 years) with T2D who had received BI‐based therapy as outpatients for ≥3 months were eligible for inclusion in the study. Study subjects were followed‐up for ≥3 months prior to enrolment at the respective study center, with HbA1c and fasting plasma glucose (FPG) measurements available 1 month before entering the study. Because the present study was an observational study, no medication was provided by the sponsor. The use of OADs and prandial insulin, as well as the BI dose, were chosen at the participating physicians\' discretion in line with treatment guidelines and local label indications.

2.4. Education and study committee {#jdb12963-sec-0011}
----------------------------------

Physician education was based on a standard T2D treatment pathway and incorporated self‐audit and regular peer‐to‐peer discussion. The treatment pathway followed 2013 CDS[6](#jdb12963-bib-0006){ref-type="ref"} (Figure [S2](#jdb12963-supitem-0001){ref-type="supplementary-material"}) and 2013 American Association of Clinical Endocrinologists/American College of Endocrinology[22](#jdb12963-bib-0022){ref-type="ref"} (Figure [S3](#jdb12963-supitem-0001){ref-type="supplementary-material"}) guidelines. Training covered offering advice on diet, smoking cessation, daily physical activity, and maintenance of a healthy weight, as well as information about insulin preparations, correct dosing, when and how to administer insulin, self‐monitoring blood glucose, and management and prevention of hypoglycemia.

Participating physicians attended an initial face‐to‐face interactive training workshop provided by the Study Committee. Participants then applied the standard T2D treatment pathway, insulin initiation and titration scheme, and appropriate patient education in outpatient practice for 6 months. During this 6‐month period, a regular self‐audit regarding implementation of the standard insulin treatment pathway was performed every month. All participating physicians were required to attend the monthly meeting to discuss any issue of BI management during daily practice, share valuable experiences, and come to potential solutions after peer‐to‐peer discussion. The principal investigator of each center was responsible for self‐audit in his or her center.

2.5. Objectives and evaluation criteria {#jdb12963-sec-0012}
---------------------------------------

The primary endpoint of BEYOND II was the percentage of hospitals meeting individual improvement goals. The goal setting was based on the proportion of patients achieving HbA1c \<7.0% (53 mmol/mol) in each hospital at the baseline sample survey. The Study Committee member and principle investigator at each study center discussed the baseline data and decided on an appropriate improvement goal for each center, taking into account relevant factors such as patient characteristics and available resources.[3](#jdb12963-bib-0003){ref-type="ref"}

Secondary endpoints included assessment of glycemic control and safety in the baseline and post‐education surveys, as indicated by mean HbA1c and FPG, the proportion of patients achieving HbA1c \<7% and FPG \<6.1 mM, and the frequency of hypoglycemic events (blood glucose ≤3.9 mM) and severe hypoglycemic events (hypoglycemic episodes requiring the assistance of another person or admission to hospital) in the 2 weeks before enrolment. Physicians\' confidence and daily practice in BI treatment were assessed by questionnaire (Figures [S4,S5](#jdb12963-supitem-0001){ref-type="supplementary-material"}).

Exploratory objectives included investigation of the relationship between hospital characteristics at the baseline survey and absolute and relative improvements in the hospital at the post‐education survey.

2.6. Statistical analysis {#jdb12963-sec-0013}
-------------------------

The primary statistical objective was to estimate the percentage of hospitals meeting individual improvement goals, which is provided with the corresponding 95% confidence intervals (CI). A sample size of 150 Tier 2 and 3 hospitals was calculated to allow estimation of two‐sided 95% CIs for the rate of hospitals that met improvement goals with a precision of approximately ±8.3%, assuming 50% of hospitals would meet improvement goals (the five county‐level hospitals were included in an exploratory group; data from these hospitals will be assessed separately).

A sample size of approximately 100 subjects per cohort in each study center was calculated to allow estimation of the two‐sided 95% CIs for the proportion of subjects achieving HbA1c \<7% (53 mmol/mol) with a precision of approximately ±10%, assuming 50% of patients would achieve HbA1c \<7% (53 mmol/mol). An HbA1c of \<7% (53 mmol/mol) was chosen in the sample size estimation because this was used to set improvement goals for all study centers.

Continuous variables are summarized using descriptive statistics as the mean ± SD or as the median (range). Major continuous variables included mean HbA1c and mean FPG. It was assumed that for the large sample size the data would be normally distributed. A two‐sample *t* test was used to compare baseline and post‐educational (6‐month) data for continuous variables.

Discrete variables are summarized in frequency tables. Major discrete variables included the percentage of patients achieving glucose goal (HbA1c \<7%), the percentage of patients with achieving the FPG goal (\<6.1 mM), hypoglycemia rate, and severe hypoglycemia rate. Chi‐squared tests were used for comparisons of baseline and post‐educational (6‐month) data.

Univariate and multivariate regression analysis were used to assess factors affecting hospitals\' absolute and relative improvements in glycemic management. The factors included in the univariate analysis were the proportion of patients achieving HbA1c \<7% at the baseline survey (top 50% vs bottom 50%), region of China (south vs north), hospital level (tertiary general hospital vs secondary general hospital), and affiliated teaching hospital of a medical university (yes vs no). The stepwise method was used to select the risk factors in multivariate analysis.

Values for missing data were not imputed unless stated otherwise.

2.7. Data accessibility {#jdb12963-sec-0014}
-----------------------

Qualified researchers may request access to patient‐level data and related study documents, including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient‐level data will be anonymized and study documents will be redacted to protect the privacy of the trial participants. Further details on Sanofi\'s data sharing criteria, eligible studies, and process for requesting access can be found at <https://www.clinicalstudydatarequest.com/> (accessed 08 July 2019).

3. RESULTS {#jdb12963-sec-0015}
==========

3.1. Primary endpoint {#jdb12963-sec-0016}
---------------------

In all, 73 Tier 2 and 3 hospitals entered the study, and 71 completed the post‐education patient enrolment. Of the 71 hospitals that completed the study, 63 were Tier 3 hospitals and 8 were Tier 2 hospitals; 34 hospitals were located in north China and 37 hospitals were located in south China; 26 were affiliated with a medical university. At the baseline survey, the proportion of patients achieving HbA1c \<7% (53 mmol/mol) was \<20% at 11 hospitals, 20%‐35% at 47 hospitals, and ≥ 35% at 13 hospitals. At the post‐education survey, the proportion of patients achieving HbA1c \<7% (53 mmol/mol) was \<20% at 5 hospitals, 20%‐35% at 30 hospitals, and ≥ 35% at 36 hospitals.

The primary endpoint was achieved by 35/71 hospitals (49.3%; 95% CI 37.2%‐61.4%). The number of hospitals with \>0% absolute improvement in the proportion of patients achieving HbA1c \<7% (53 mmol/mol) was 58/71 (81.7%), of which 41 (70.7%) achieved an improvement of \>5% (Table [S2](#jdb12963-supitem-0001){ref-type="supplementary-material"}). Detailed improvement data for each hospital are provided in Table [S3](#jdb12963-supitem-0001){ref-type="supplementary-material"}.

3.2. Factors related to hospital improvement {#jdb12963-sec-0017}
--------------------------------------------

In all, 71 hospitals were included in the analysis of the relationship between hospital characteristics at the baseline sample survey and absolute or relative improvement at the post‐education sample survey. The definition of improvement was based on the change in the proportion of patients achieving HbA1c \<7% between the baseline and post‐education sample surveys in the participating hospitals. The distribution of hospitals by absolute improvement (no improvement, ≤10% and \> 10% improvement) differed significantly between the top 50% and bottom 50% of hospitals stratified by proportion of patients achieving HbA1c \<7% at the baseline survey. A similar difference was observed between hospitals affiliated with medical universities and those that were not. In contrast, no difference in distribution was observed according to region or hospital tier (Table [1](#jdb12963-tbl-0001){ref-type="table"}). Similar results were observed for relative improvement (no improvement, ≤30% and \>30% improvement; Table [1](#jdb12963-tbl-0001){ref-type="table"}).

###### 

Distribution of hospitals by absolute and relative improvement

  Hospital characteristics at baseline survey                      Hospitals by absolute improvement   Hospitals by relative improvement                                                            
  ---------------------------------------------------------------- ----------------------------------- ----------------------------------- ----------- ------- ------------ ----------- ----------- -------
  Proportion of patients achieving HbA1c \<7% at baseline survey                                       0.047                                                                0.013                   
  Top 50%                                                          10 (76.9)                           12 (52.2)                           13 (37.1)           10 (76.9)    14 (58.3)   11 (32.4)   
  Bottom 50%                                                       3 (23.1)                            11 (47.8)                           22 (62.9)           3 (23.1)     10 (41.7)   23 (67.6)   
  Region of China                                                                                                                                      0.523                                        0.382
  South                                                            7 (53.8)                            14 (60.9)                           16 (45.7)           7 (53.8)     15 (62.5)   15 (44.1)   
  North                                                            6 (46.2)                            9 (39.1)                            19 (54.3)           6 (46.2)     9 (37.5)    19 (55.9)   
  Hospital level                                                                                                                                       0.222                                        0.198
  Tertiary general hospital                                        13 (100.0)                          21 (91.3)                           29 (82.9)           13 (100.0)   22 (91.7)   28 (82.4)   
  Secondary general hospital                                       0                                   2 (8.7)                             6 (17.1)            0            2 (8.3)     6 (17.6)    
  Affiliated to medical university                                                                                                                     0.002                                        0.003
  Yes                                                              10 (76.9)                           4 (17.4)                            12 (34.3)           10 (76.9)    5 (20.8)    11 (32.4)   
  No                                                               3 (23.1)                            19 (82.6)                           23 (65.7)           3 (23.1)     19 (79.2)   23 (67.6)   

*Note*: Unless indicated otherwise, data are given as n (%), where n refers to the number of hospitals throughout. *P*‐values were calculated using Chi‐squared tests.

Multivariate analysis revealed that only the variable "hospitals stratified by proportion of patients achieving HbA1c \<7% at baseline survey (top 50% vs bottom 50%)" was significantly negatively associated with both absolute improvement (odds ratio \[OR\] 0.33; 95% CI 0.13‐0.83; *P* = 0.018) and relative improvement (OR 0.25; 95% CI 0.10‐0.64; *P* = 0.004; Table [2](#jdb12963-tbl-0002){ref-type="table"}). No association was found between hospital region, hospital level, or affiliation status with medical universities.

###### 

Logistic regression analysis of factors associated with hospitals\' absolute and relative improvements

                                                                                           Univariate analysis   Multivariate analysis                       
  ---------------------------------------------------------------------------------------- --------------------- ----------------------- ------------------- -------
  Factors associated with absolute improvement                                                                                                               
  Proportion of patients achieving HbA1c \<7% at baseline survey (top 50% vs bottom 50%)   0.33 (0.13, 0.83)     0.018                   0.33 (0.13, 0.83)   0.018
  Region of China (south vs north)                                                         0.67 (0.28, 1.63)     0.382                                       
  Hospital level (tertiary general hospital vs secondary general hospital)                 0.26 (0.05, 1.40)     0.116                                       
  Affiliated to medical university (yes vs no)                                             0.46 (0.18, 1.14)     0.095                                       
  Factors associated with relative improvement                                                                                                               
  Proportion of patients achieving HbA1c \<7% at baseline survey (top 50% vs bottom 50%)   0.25 (0.10, 0.64)     0.004                   0.25 (0.10, 0.64)   0.004
  Region of China (south vs north)                                                         0.62 (0.26, 1.51)     0.294                                       
  Hospital level (tertiary general hospital vs secondary general hospital)                 0.24 (0.04, 1.32)     0.101                                       
  Affiliated to medical university (yes vs no)                                             0.40 (0.16, 1.01)     0.052                                       

*Note*: In multivariate analysis, the stepwise method was used to select the risk factors from univariate analysis.

Abbreviations: CI, confidence interval; OR, odds ratio.

3.3. Patient profiles at the baseline and post‐education sample surveys {#jdb12963-sec-0018}
-----------------------------------------------------------------------

In all, 6561 patients were enrolled in the baseline sample survey, with 6386 evaluable patients. Following the education program, 6413 patients were enrolled into the post‐education sample survey, with 6353 evaluable patients. Overall, the demographics of patients in the baseline and post‐education surveys were comparable, with a similar mean age, body mass index, duration of T2D, prevalence of diabetic complications, and mean daily BI dose (Table [S4](#jdb12963-supitem-0001){ref-type="supplementary-material"}).

Overall, in the post‐education sample survey, patients\' glycemic control was improved compared with the baseline sample survey (Table [3](#jdb12963-tbl-0003){ref-type="table"}). Compared with baseline, patients enrolled in the post‐education survey had a lower mean HbA1c level (8.10 ± 1.73% \[65 mmol/mol\] vs 7.72 ± 1.58% \[61 mmol/mol\]; *P* \< 0.001) and a higher proportion achieved HbA1c \<7% (53 mmol/mol; 27.2% vs 36.5%; *P* \< 0.001). Similarly, compared with the baseline survey, patients in the post‐education survey had a lower mean FPG (9.10 vs 8.44 mM; *P* \< 0.001) and a greater proportion achieved FPG \<6.1 mM (15.6% vs 19.6%; *P* \< 0.001) and FPG \<7.0 mM (29.5% vs 37.2%; *P* \< 0.001). Finally, the rate of hypoglycemia was lower in the post‐education survey, although this difference did not reach statistical significance (4.4% vs 3.8%; *P* = 0.077).

###### 

Summary of glucose management at the baseline and post‐education sample surveys

  Variable                                                       Baseline sample survey (*n* = 6386)   Post‐education sample survey (*n* = 6353)   Difference (95% CI)    *P*‐value[a](#jdb12963-note-0010){ref-type="fn"}
  -------------------------------------------------------------- ------------------------------------- ------------------------------------------- ---------------------- --------------------------------------------------
  Mean (± SD) HbA1c (%)                                          8.10 ± 1.73                           7.72 ± 1.58                                 −0.38 (−0.43, −0.32)   \<0.001
  HbA1c \<7%                                                     1740 (27.2)                           2322 (36.5)                                 9.3% (7.7%, 10.9%)     \<0.001
  Adjusted HbA1c target[b](#jdb12963-note-0011){ref-type="fn"}   2183 (34.2)                           2743 (43.2)                                 9.0% (7.3%, 10.7%)     \<0.001
  Mean (± SD) FPG (mM)                                           9.10 ± 3.58                           8.44 ± 3.17                                 −0.66 (−0.78, 0.54)    \<0.001
  FPG \<6.1 mM                                                   994 (15.6)                            1247 (19.6)                                 4.1% (2.7%, 5.4%)      \<0.001
  FPG \<7.0 mM                                                   1883 (29.5)                           2363 (37.2)                                 7.7% (6.1%, 9.3%)      \<0.001
  Incidence of hypoglycemia                                      282 (4.4)                             241 (3.8)                                   −0.6% (−1.3%, 0.1%)    0.077

*Note*: Unless indicated otherwise, data are given as *n* (%).

Abbreviations: CI, confidence interval; FPG, fasting plasma glucose.

Chi‐squared test for categorical variables, Student\'s *t* test for continuous variables.

Adjusted HbA1c target calculated using an adjusted HbA1c target of ≤7.5% (58 mmol/mol) for patients with existing cardiovascular disease or age ≥ 65 years.

At hospitals that met individualized improvement targets, compared with baseline, the proportion of patients in the post‐education survey achieving HbA1c \<7% (53 mmol/mol) was significantly higher (25.6% vs 43.1%; *P* \< 0.001), whereas mean HbA1c (8.10% \[65 mmol/mol\] vs 7.46% \[58 mmol/mol\]; *P* \< 0.001) and FPG (9.02 vs 8.04 mM; *P* \< 0.001) levels were significantly lower (Table [S5](#jdb12963-supitem-0001){ref-type="supplementary-material"}). In contrast, at hospitals not meeting targets, the proportion of patients in the baseline and post‐education surveys achieving HbA1c \<7% (53 mmol/mol) was similar (29.1% vs 29.8%; *P* = 0.537), and differences in mean HbA1c (8.08 \[61 mmol/mol\] vs 7.99% \[64 mmol/mol\]; *P* = 0.045) and FPG (9.15 vs 8.85 mM; *P* \< 0.001) levels were lower in magnitude.

3.4. Physician questionnaire analysis {#jdb12963-sec-0019}
-------------------------------------

In all, 793 physicians were included in the study at baseline, of whom 764 took part in the 6‐month education intervention and 723 had evaluable data. According to the baseline survey, 550 (76.1%) physicians self‐reported "confidence in most cases" in initiating BI therapy; this number increased to 602 (83.3%; *P* = 0.002) at the post‐education survey (Figure [1](#jdb12963-fig-0001){ref-type="fig"}A). Similarly, the number of physicians reporting 'confidence in most cases' in management of hypoglycemia also increased between the baseline and post‐education surveys (569 \[78.7%\] vs 607 \[84.0%\]; *P* = 0.007; Figure [1](#jdb12963-fig-0001){ref-type="fig"}G). However, there was no significant difference in the proportion of physicians "confident in most cases" about reaching FPG goals via BI titration between the baseline and post‐education surveys (80.2% vs 82.6%; *P* = 0.076; Figure [1](#jdb12963-fig-0001){ref-type="fig"}D). Subgroup analysis revealed that study centers meeting individualized improvement targets had significant changes in treatment confidence (Figure [1](#jdb12963-fig-0001){ref-type="fig"}B,E,H), compared with no significant changes in centers not meeting the improvement targets (Figure [1](#jdb12963-fig-0001){ref-type="fig"}C,F,I).

![Results of physician (*n* = 723) confidence in the use of basal insulin, assessed by questionnaires, for all study centers, those that achieved individualized improvement targets (*n* = 356), and those that did not (*n* = 367) at baseline and after the 6‐month education intervention. A‐C, Initiation of basal insulin; D‐F, titration of insulin dose to meet fasting plasma glucose (FPG) targets; G‐I, management of hypoglycemia](JDB-12-66-g001){#jdb12963-fig-0001}

A survey of daily insulin treatment practice revealed that the proportion of physicians who "always" (100% of the time) or "usually" (80%‐99% of the time) prescribed BI as initial treatment and titrated BI dose to achieve FPG \<6.1 mM was higher at the post‐education than baseline survey (Figure [2](#jdb12963-fig-0002){ref-type="fig"}A,D). Furthermore, the proportion of physicians who 'always' or 'usually' replaced BI with premixed insulin showed a small decrease after education compared with baseline (Figure [2](#jdb12963-fig-0002){ref-type="fig"}G). The initiation of BI for individuals not achieving HbA1c and FPG targets was largely comparable at baseline and after the education intervention (Figure [2](#jdb12963-fig-0002){ref-type="fig"}J). In addition, physicians at study centers that met improvement targets showed more marked changes in clinical practice in terms of BI use following the education intervention (Figure [2](#jdb12963-fig-0002){ref-type="fig"}B,E,H,K). At centers not meeting targets there was no significant change in clinical practice (Figure [2](#jdb12963-fig-0002){ref-type="fig"}C,F,I,L).

![Physician (*n* = 723) clinical practice in the use of basal insulin, assessed by questionnaires, for all study centers, for those that achieved individualized improvement targets (*n* = 356), and those that did not (*n* = 367). A‐C, Use basal insulin to initiate insulin treatment; D‐F, titrate basal insulin using fasting plasma glucose (FPG) \<6.1 mM; G‐I, use premixed insulin to replace basal insulin; J‐L, use basal insulin for individuals who do not achieve HbA1c and FPG targets](JDB-12-66-g002){#jdb12963-fig-0002}

4. DISCUSSION {#jdb12963-sec-0020}
=============

There is currently a global need to improve rates of glycemic control among patients with T2D receiving BI‐based treatment.[10](#jdb12963-bib-0010){ref-type="ref"}, [11](#jdb12963-bib-0011){ref-type="ref"}, [12](#jdb12963-bib-0012){ref-type="ref"} To the best of the authors\' knowledge, BEYOND II is the first study to demonstrate the effectiveness of physician‐targeted education for improving glycemic management of patients with T2D receiving BI. The primary endpoint revealed that the 6‐month education program led to achievement of individualized improvement goals at approximately 50% of hospitals. The primary endpoint was further supported by the finding that the proportion of patients achieving HbA1c \<7% at the post‐education sample survey was higher than at the baseline sample survey. Furthermore, multivariate analysis revealed that hospitals with poor glycemic control at the baseline survey had a higher possibility of improving after the 6‐month education intervention; these results indicate that physician‐targeted education may be more effective at hospitals with poor glycemic management at the baseline survey.

The primary objective of this study was to observe changes in glucose management by physicians and hospitals after education. Two sample surveys were the best strategy to meet this objective. During the 6‐month education period, physicians applied the standard treatment procedures recommended in training, which may have improved glucose management and benefitted all the patients treated by them. Following‐up the same 100 patients would have only yielded data on changes in HbA1c in these patients. To ensure all the enrolled patients were affected by the education intervention, only patients who were being followed‐up at the study at site and receiving BI therapy for ≥3 months were included in the study. Thus, the patients received treatment from the trained physicians for at least 3 months before the post‐education survey.

One unique strength of the BEYOND II study is using individualized improvement goals as the primary endpoint. The use of individualized goals provides physicians with a clear overview of glycemic control at their hospital, and gives them tangible improvement goals to achieve. In contrast, all previous quality improvement studies used HbA1c reductions in overall patients as the primary endpoint.[10](#jdb12963-bib-0010){ref-type="ref"}, [11](#jdb12963-bib-0011){ref-type="ref"}, [12](#jdb12963-bib-0012){ref-type="ref"}, [14](#jdb12963-bib-0014){ref-type="ref"}, [18](#jdb12963-bib-0018){ref-type="ref"} Another important strength of this study was the incorporation of multiple elements in the physician‐targeted education, including the use of evidence‐based guidelines and training on how to educate patients, both of which have been shown to be effective in improving diabetes care.[14](#jdb12963-bib-0014){ref-type="ref"}, [18](#jdb12963-bib-0018){ref-type="ref"} Moreover, the implementation of regular peer‐to‐peer review and discussion are suggested as particularly useful in stimulating changes in physicians\' habits.[23](#jdb12963-bib-0023){ref-type="ref"}, [24](#jdb12963-bib-0024){ref-type="ref"}, [25](#jdb12963-bib-0025){ref-type="ref"} Finally, this study included a self‐assessment of physicians\' confidence and clinical practice in BI use via the use of a questionnaire. These questionnaires enabled investigation of the relationship between physicians\' self‐assessed confidence, their behavior in real clinical practice, and the outcomes of diabetes care at their hospitals. The final results demonstrated that physicians\' confidence and behavior change were positively associated with improvements in glycemic control at their hospitals.

However, the BEYOND II study may have limitations. First, the lack of a control group did not allow direct comparison of the education vs no education or an alternative education. Second, two separate groups of patients were enrolled at the baseline and post‐education surveys, which may have resulted in selection bias. To reduce the selection bias of the two surveys, a consecutive 2‐month enrollment was adopted. A longer enrolment period (3‐5 months) would have given physicians a chance to select patients with better glycemic control to meet their post‐education target. However, we acknowledge that the selection bias could not be totally avoided in this study. Third, the post‐education survey was conducted immediately after the 6‐month education intervention. We acknowledge that conducting another 2‐month survey 1 year after the completion of the education intervention would have enable us to demonstrate whether the effects of the education intervention are sustainable. Finally, the findings could have been affected by the Hawthorne effect because the physicians were aware of being under observation.[26](#jdb12963-bib-0026){ref-type="ref"} However, a previous study reported limited influence of the Hawthorne effect on patient‐physician visits, except for the subgroup of vulnerable patients, where it slightly affected the observations.[27](#jdb12963-bib-0027){ref-type="ref"}

In conclusion, physician‐targeted education improved glycemic management of Chinese patients with T2D in 71 hospitals across China and appeared to be more effective at hospitals with poor mean glycemic control at baseline. However, future studies are warranted to confirm the program\'s effectiveness (eg, using control groups) and to establish the effectiveness of physicians\' education in the whole country.
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